Literature DB >> 12805323

Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?

William F Anderson1, Kenneth C Chu, Shine Chang.   

Abstract

PURPOSE: Inflammatory breast carcinoma (IBC) and noninflammatory locally advanced breast carcinoma (LABC) are both associated with poor prognosis; however, whether they are distinct clinicopathologic entities remains controversial.
MATERIALS AND METHODS: To determine whether IBC and LABC were different, we compared tumor characteristics, prognosis, and age-specific incidence rate patterns in the Surveillance, Epidemiology, and End-Results program. An age of 50 years served as a surrogate marker for menopause.
RESULTS: Younger age at diagnosis, poorer tumor grade, and negative estrogen receptors (ERs) were more predictive of IBC (n = 2,237) than of LABC (n = 7,985). Breast carcinoma survival was worse for patients with IBC than for those with LABC (log-rank test, P <.0001). Age-specific incidence rates for IBC increased until 50 years and then flattened, whereas rates for LABC increased for all ages. When rates for LABC were stratified by estrogen receptor-positive (ERP) and -negative (ERN) expression, rates for ERP and ERN diverged; that is, rates for ERP increased with advancing age, whereas rates for ERN flattened after 50 years. When rates for IBC were stratified by ER expression, rates for both ERP and ERN flattened after 50 years of age.
CONCLUSION: IBC and LABC seemed to be distinct biologic entities, as indicated by different prognostic factor profiles and age-specific incidence rate patterns. Rates that increased before 50 years and then stabilized, possibly indicated that premenopausal exposures had a greater effect on maintaining rates for IBC than for LABC.

Entities:  

Mesh:

Year:  2003        PMID: 12805323     DOI: 10.1200/JCO.2003.07.082

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  38 in total

1.  Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer.

Authors:  Catherine Schairer; Shahinaz M Gadalla; Ruth M Pfeiffer; Steven C Moore; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-13       Impact factor: 4.254

2.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

3.  Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2012-06-26       Impact factor: 4.872

4.  Inflammatory Breast Cancer Outcomes in a Contemporary Series.

Authors:  Elizabeth Pan; Lily Tung; Omar Ragab; Elise Morocco; Julie Wecsler; Richard Sposto; Akshara Raghavendra; Eugene Chung; Julie E Lang
Journal:  Anticancer Res       Date:  2017-09       Impact factor: 2.480

5.  Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer.

Authors:  Carolyn S Hall; Mandar Karhade; Barbara A Laubacher; Henry M Kuerer; Savitri Krishnamurthy; Sarah DeSnyder; Amber E Anderson; Vicente Valero; Naoto T Ueno; Yisheng Li; Xiao Su; Anthony Lucci
Journal:  J Natl Cancer Inst       Date:  2015-09-14       Impact factor: 13.506

6.  What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?

Authors:  Dora Il'yasova; Sharareh Siamakpour-Reihani; Igor Akushevich; Lucy Akushevich; Neil Spector; Joellen Schildkraut
Journal:  Breast Cancer Res Treat       Date:  2011-08-18       Impact factor: 4.872

7.  X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.

Authors:  Katherine M Aird; Rami B Ghanayem; Sharon Peplinski; Herbert K Lyerly; Gayathri R Devi
Journal:  Mol Cancer Ther       Date:  2010-04-20       Impact factor: 6.261

8.  Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; Mousumi Banerjee; Laura S Rozek; David Schottenfeld; Joe B Harford; Sofia D Merajver
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-25       Impact factor: 4.254

9.  Risk factors for inflammatory breast cancer and other invasive breast cancers.

Authors:  Catherine Schairer; Yan Li; Peter Frawley; Barry I Graubard; Robert D Wellman; Diana S M Buist; Karla Kerlikowske; Tracy L Onega; William F Anderson; Diana L Miglioretti
Journal:  J Natl Cancer Inst       Date:  2013-09-18       Impact factor: 13.506

10.  The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.

Authors:  J Lemieux; M Clemons; L Provencher; S Dent; J Latreille; J Mackey; K I Pritchard; D Rayson; Sh Verma; Su Verma; B Wang; S Chia
Journal:  Curr Oncol       Date:  2009-09       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.